The safety of nivolumab for the treatment of advanced non-small cell lung cancer

G Metro, B Ricciuti, M Brambilla, S Baglivo… - Expert Opinion on …, 2017 - Taylor & Francis
ABSTRACT Introduction: Immune checkpoint blockaders (ICBs) act by unbalancing the
immune system, thus favoring the development of an immune-mediated antitumor effect …
被引用次数：11 相关文章

The safety of nivolumab for the treatment of advanced non-small cell lung cancer

G Metro, B Ricciuti, M Brambilla… - Expert opinion on …, 2017 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockaders (ICBs) act by unbalancing the immune system, thus favoring
the development of an immune-mediated antitumor effect. ICBs targeting the programmed …

[引用][C] The safety of nivolumab for the treatment of advanced non-small cell lung cancer

G Metro, B Ricciuti, M Brambilla, S Baglivo… - Expert Opinion on Drug …, 2016 - cir.nii.ac.jp
The safety of nivolumab for the treatment of advanced non-small cell lung cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

The safety of nivolumab for the treatment of advanced non-small cell lung cancer.

G Metro, B Ricciuti, M Brambilla, S Baglivo… - Expert Opinion on …, 2016 - europepmc.org
Immune checkpoint blockaders (ICBs) act by unbalancing the immune system, thus favoring
the development of an immune-mediated antitumor effect. ICBs targeting the programmed …